By: Izaz Ul Islam
Summary
This report examines ten emerging technologies identified by the World Economic Forum (WEF) as poised to transform energy, environment, biotechnology, artificial intelligence, and information security by the early 2030s. These include everything-to-grid energy (making buildings, vehicles and devices into active grid resources), direct lithium extraction (rapid, water-efficient recovery of battery metals from brines), passive radiative cooling materials (coatings and surfaces that cool by emitting infrared heat to sky), PFAS destruction (breaking the strong carbon-fluorine bonds of “forever chemicals” in water), precision fermentation (using engineered microbes to produce proteins, drugs and chemicals), exosome drug delivery (using the body’s own nanoscale vesicles to carry therapeutics across biological barriers), personalized mRNA cancer vaccines (tailoring mRNA immunotherapies to each patient’s tumor mutations), quantum simulation for drug discovery (using quantum computers to model complex molecules directly), world models in AI (AI systems learning rich physical representations from multimodal data), and lattice-based cryptography (quantum-resistant encryption hiding data in high-dimensional “noise”). For each, we provide an in-depth technical overview, key principles, recent advances (2021–2026), representative sources, applications, challenges, societal implications, commercialization status (including lead organizations), and future outlook.
1. Everything-to-Grid Energy
Overview: “Everything-to-grid” energy means treating every energy-consuming or storing device (homes, buildings, EVs, appliances) as a potential grid asset. In this paradigm, batteries and power electronics do not simply consume electricity; they can absorb or inject power on command, helping balance supply and demand in real time. Electric vehicles (EVs) become movable storage, homes with solar+batteries become mini power plants, and flexible loads (e.g. smart appliances) help absorb peaks. The goal is a distributed network of intelligence: “Every building, vehicle and device becomes a place that can store power, return it and help balance supply and demand in real time, turning the grid into a network of intelligent nodes”. Key principles include bidirectional power electronics (vehicle-to-grid, building-to-grid), grid-aware control software, and new battery chemistries that enable long life and fast charge/discharge.
Recent Advances: Several advances (2021–2026) underpin this trend. New battery materials (e.g. lithium iron phosphate, sodium-ion) reduce reliance on scarce metals and lower costs. For example, by 2025 LFP batteries surpassed nickel-cobalt (NMC) batteries in EV production, reflecting this shift. Power electronics have improved: wide-bandgap semiconductors (SiC, GaN) drastically cut losses in inverters, making round-trip storage over 98% efficient. Software and control algorithms now allow distributed resources to actively stabilize frequency and voltage, rather than passively “dump” power. Utilities and regulators are updating compensation: some pay for energy delivered from storage rather than only for stored kWh. V2G pilot projects and networked batteries are growing: in 2025 Australian programs recruited 180,000 home batteries into grid services, and companies like Eaton and Gridserve are deploying “buildings-as-grid” platforms.
Applications: Everything-to-grid enables many applications. EVs and second-life vehicle batteries can provide peak shaving and grid reserves; commercial buildings and campus generators can form microgrids offering black-start and demand response. Ancillary services (frequency regulation) can be delivered by fleets of assets in unison. For instance, OpenADR standards note that “EV batteries can act as flexible, distributed energy capacity that helps support reliability, manage peaks, and improve the integration of variable renewables”. On a community scale, coordinated home solar+storage installations can form virtual power plants to buffer renewables (as trialed in California and Australia). Big data analytics and AI can optimize when thousands of devices charge or discharge to follow grid needs.
Limitations/Challenges: Key challenges include battery degradation (frequent cycling can shorten life), unclear business models, and cybersecurity risks from an interconnected grid. If each device is an IoT node, attackers might exploit weak links. Also, fair compensation is evolving: we need standards to pay owners for flexible capacity, not just stored kWh. Interoperability is an issue—numerous vendors (inverters, EV chargers, thermostats) must adhere to common communication protocols. Deploying this at scale requires utility upgrades and regulatory changes (e.g. time-of-use pricing and V2G tariffs). Without coordination, assets could end up competing rather than forming a cohesive “resilience system”. Researchers caution that fragmented markets or inadequate incentives could fragment the grid of resources rather than unify it.
Ethical/Societal Implications: Everything-to-grid can democratize energy: prosumers (homeowners) gain value from selling power, potentially reducing energy bills and expanding renewable use. It can also enhance resilience, buffering storm outages. However, it could widen inequality if only wealthier households (owning assets) can profit, or if rural areas with fewer resources are left behind. Data privacy and cyber-safety are major societal concerns: personal consumption patterns (when you charge your car or run an appliance) could be exposed if not properly managed. We must ensure secure standards so citizens’ devices aren’t hijacked or surveilled. On the positive side, the shift supports climate goals by better integrating renewables and reducing reliance on peaker plants.
Commercialization & Leading Organizations: Elements of everything-to-grid are already commercial. V2G and grid-integrated batteries are deployed by companies like Nuvve, ABB, Siemens, and Eaton. Tesla and ChargePoint offer bi-directional EV chargers. Energy software firms (e.g. AutoGrid, Enbala) aggregate DERs. Grid operators in California, UK and Australia have launched tariffs for “virtual power plants”. Research initiatives include the US DOE’s Grid Modernization Lab Consortium. The technology readiness is high (TRL 7–9 for individual pieces like EV chargers and smart inverters) with broader grid-coordination systems maturing (target TRL ~7 by 2025). Full integration (millions of devices coordinated) is likely mid- to late-2030s.
Future Directions: Research will focus on advanced batteries (solid-state, metal-air) for longer life and faster discharge, AI algorithms for real-time orchestration, and robust cyber-physical standards. Policies will need to evolve (transactive energy markets, cybersecurity frameworks). A key open question is business models: how to equitably allocate value among utilities, customers and aggregators. Future innovations may include autonomous microgrids that island seamlessly when needed, and dynamic community storage tariffs. Overall, this technology trend converges with decarbonization: as renewables penetration rises, the need for pervasive, intelligent flexibility makes everything-to-grid increasingly vital.
2. Direct Lithium Extraction (DLE)
Overview: Conventional lithium production relies on massive evaporation ponds in brine-rich deserts. These take 12–18 months per cycle, use huge land areas and water, and recover only ~40–50% of Li. Direct lithium extraction (DLE) uses engineered filters, membranes, solvents or electrochemical cells to rapidly extract Li⁺ ions from brines in hours to days, returning cleaned brine underground. Key principles include highly selective sorbent materials (e.g. ion-exchange resins, metal oxides), solvent extraction chemistry, membrane separation, and electrochemical capture. Each DLE approach can target specific ion chemistries. For example, lithium manganese oxide (LMO) adsorbents have shown high selectivity. Crucially, DLE can reach novel sources: geothermal fluids, oilfield brines and even wastewater—where evaporation ponds won’t work. By enabling localized, modular extraction, DLE can democratize supply.
Recent Advances: Since 2021, many breakthroughs have pushed DLE forward. New adsorbent materials (e.g. layered oxides, metal–organic frameworks, tailored clays) have boosted selectivity and capacity. Membrane technologies (nanofiltration, electrodialysis) have improved to let only Li⁺ pass while rejecting other ions. Advanced electrochemical cells can now directly plate lithium metal or hydroxide out of brine. A 2025 Nature Communications paper demonstrated electro-driven extraction of battery-grade LiOH from geothermal brine (an approach unthinkable a decade ago). Industrial pilots began operations: in 2024 Eramet’s Centenario-Ratones plant in Argentina (altitude 4000m) became the first commercial DLE facility without ponds. In California’s Salton Sea, EnergySource Minerals is producing power and lithium from hot brine concurrently. These projects show >80% Li recovery and battery-grade product. Meanwhile, the industry is scaling: firms like Lilac Solutions, EnergyX, Standard Lithium, and Desert Tech are raising funds for pilots. Tech journals report that DLE adoption has less than 10% market share but is growing rapidly.
Principles and Sources: A 2025 review notes DLE’s advantages: recovery rates of 75–99.9% in hours/days (vs months/years for ponds), with minimal land use. DLE excels on low-concentration brines (e.g. Mg-rich geothermal fluids) that normal methods ignore. At the heart are processes like solvent extraction (using organic phases to capture Li⁺), ion-exchange adsorption (with high-entropy ceramics or LMOs), membrane separation, and electrochemical “electrosorption” cells. Only adsorption (using ion-exchange resins) has seen scaled use so far; other methods are rapidly advancing in labs. Recent reviews discuss strategies like doping adsorbents to prevent degradation and hybrid solar-driven systems that also desalinate water.
Applications: DLE can diversify lithium supply. It works in traditional salar brines (e.g. Atacama, brine after partial evaporation) but also in new contexts: geothermal brines (e.g. Salton Sea, USA) and oilfield produced water have been validated. It opens non-desert sources (e.g. Great Salt Lake, Arkansas). DLE is also promising for recycling: extracting Li from spent batteries or recycled leachates. In practice, hybrid flowsheets are emerging: for example, pre-filtering and concentrating brine, then using a sequence of adsorption+membrane steps to get >90% extraction. Because it produces an intermediate (often lithium chloride) already near battery-grade, DLE can shorten the refining chain and reduce transport: extraction and processing may co-locate.
Limitations/Challenges: Many DLE methods are still unproven at scale. Adsorbents must resist fouling and handle high Mg/Li ratios; only a few mineral chemistries work well in practice. Energy use is higher per kg Li than ponds (especially if not run on renewables). Water and waste brines need careful management. Capital costs are steep and the economics depend on Li price: currently low lithium prices (<$5000/t LCE) have delayed investment. Regulatory frameworks (water rights, environmental review) are underdeveloped in many countries outside Chile/Argentina. Social license is a concern: some communities might resist “industrial” brine processing. Moreover, DLE’s viability varies strongly by source chemistry and location.
Ethical/Societal Implications: DLE can reduce the land/water footprint of mining, alleviating competition for scarce water in deserts (a pressing social/environmental issue in South America). It could help meet clean energy goals without worsening local water stress. However, it could also disrupt communities built around evaporation mining; new refining hubs might form far from traditional miners. Governance issues include transparency in source brine contracts and potential nuclear-laced wastes (if geothermal). On balance, DLE promises a more sustainable and secure supply of critical battery materials, possibly enabling greater domestic production in countries like the US and EU and reducing reliance on China.
Commercialization & Leading Organizations: A number of companies are racing to commercialize DLE. Eramet and Rio Tinto have pilot plants in South America; Standard Lithium in Arkansas; EnergySource Minerals (Chevron-backed) at Salton Sea; and Lilac Solutions, EnergyX, Desert Tech in R&D phases. With NIST standards enabling battery manufacturing, and US/Canadian funding (IRA, IPCEI) prioritized battery supply chain, major automakers (GM, Ford) are investing in DLE startups. The US Dept. of Energy (ARPA-E) and EU support several DLE projects. TRL is mixed: adsorption and solvent extraction pilots are around TRL 7–8, while nascent electrochemical methods are TRL 4–6. We expect full commercial adoption at scale around 2030–2035, with earlier niche deployment (2026–2028).
Future Directions: Research will continue on novel sorbents (graphene oxide, bio-sorbents), solid-state electrochemical cells, and integrated energy (solar or geothermal heat-driven) systems. Combining DLE with desalination for co-produced fresh water (as suggested by solar DLE) is attractive. Machine-learning is being applied to predict optimal materials for given brine chemistries. Policy actions include incentivizing domestic refining capacity to complement DLE extraction. Ultimately, the aim is a diversified lithium landscape, with extraction and refining co-located, slashing costs and carbon footprint relative to today’s long supply chains.
3. Passive Radiative Cooling Materials
Overview: Passive radiative cooling refers to materials engineered to shed heat by emitting infrared radiation to the cold sky, while reflecting solar radiation. In practice, a rooftop paint or coating can cool below ambient air temperature without electricity, by radiating heat in the atmospheric transparency window (8–13 μm) where the atmosphere is most IR-transparent. Key principles are high solar reflectivity (>90%) and high thermal emissivity in infrared bands. Bio-inspired designs use microstructures or pigments to reflect visible/near-IR sun and emit mid-IR heat. The effect works day or night: at night it simply radiates heat, and during the day high solar reflection helps the coating stay cool even under sunlight.
Recent Advances: In the past five years, novel cool paints and films have been commercialized. For example, an SRI International “Self-Cooling Paint™” released in 2023 uses polymeric microspheres to achieve 88–95% solar reflectance, cooling surfaces by 5–12°C. Similarly, researchers reported paints reaching 94–96% reflectance and >95% IR emissivity. Advances also include transparent radiative cooling windows and fabrics. Critically, large players have written these technologies into building codes: “California’s Energy Code requires cool roof materials on most commercial and high-rise buildings” and China has added radiative cooling specs to national green building standards. In effect, radiative cooling has moved from lab curiosity to a recognized energy code technology.
Applications: Passive cool materials can reduce air-conditioning loads by lowering surface temperatures. Applied as roof coatings or facade paint, they can cut peak cooling energy by ~20–40% in hot sunny climates. They are used on residential and commercial buildings, parked cars, telecom enclosures and even wearables (e.g. cooling fabrics for clothing or tents). For example, SkyCool Systems (2023 launch) makes roof panels that cool data center condensers. In space technology, passive thermal control is standard (spacecraft radiators). On Earth, clearly-pigmented cool paints (blue/green) were developed to let designers avoid plain white. SRI’s paint even gained a remarkable market foothold: it was adopted by contractors on large buildings in 2023. In addition, “cool pavements” embedding reflective aggregates are under trial. In tropical agriculture, radiative cooling nets over greenhouses can protect crops from heat stress at night. Overall, every context needing cooling (buildings, vehicles, machinery) is a candidate.
Limitations/Challenges: Performance depends on weather: high humidity or cloud cover reduces sky exposure, cutting effectiveness. Dust accumulation on surfaces also degrades performance, requiring cleaning. Radiative cooling mostly yields a few degrees’ cooling (not refrigeration), so on very hot days or for high heat loads it must work alongside active cooling. Costs of specialty materials (silica microspheres, polymers) are higher than ordinary paints (~$5–10/m² vs <$1/m²), though mass production is lowering costs. Scaling up production capacity remains a challenge given current early-stage manufacturing. Color range is limited (deep reds are hard to make reflective). There are also “urban canyon” issues in cities where sky view is blocked. Finally, long-term durability and UV stability of new materials require testing.
Ethical/Societal Implications: Passive cooling can dramatically reduce energy consumption and peak electricity demand for air conditioning, lowering greenhouse emissions. In developing countries with strong cooling needs, widespread use could improve comfort and productivity. Ethically, it is a rather low-risk, positive technology: it uses no power or chemicals and works everywhere. By reducing heat stress, it has public health benefits. On the other hand, it may marginally increase night-time radiative heat loss from urban areas, slightly affecting local microclimates (though beneficially by mitigating urban heat islands). Ensuring affordable access is important so low-income households can benefit. Manufacturing environmental impact (polymer production) must be managed, but overall life-cycle analyses show net energy savings.
Commercialization & Leading Organizations: Cool roofing is already mainstream where mandated by code (California, parts of China, Mediterranean Europe). Major building-material firms (e.g. GAF, KCC, Toyo Ink) offer cool-roof products. Startups like SkyCool and Radiant (acquired by L’Oreal for fabrics) have raised funding. Paint companies such as BASF are developing formulations. Research institutions like Purdue and Berkeley Advanced Groups are advancing materials (e.g. multilayer photonic films). TRL: high for conventional cool roofs (~9), moderate (~7–8) for novel high-performance paints. Cool windows (transparent), climate computing models and smart glazing are TRL 4–6. Widespread retrofits of existing buildings are just beginning (2018 IRC building code updates); full saturation could take until 2030–35.
Future Directions: Next-generation research is pursuing dynamic radiative cooling (materials that switch IR emissivity, e.g. electrochromic surfaces for day/night optimization) and integrating cooling with photovoltaic systems (cool solar panels improve efficiency). Hybrid cool-heat recovery systems can turn nighttime cooling into thermal storage. Better understanding of ecosystem effects (urban albedo) will guide deployment. Policymakers may include cool coatings in more energy standards. In computing, applying world-model AI to optimize building-scale thermal flows could further enhance impact. Overall, passive radiative cooling is poised to scale up as part of sustainable building design, with potential to significantly shave peak demand and flatten grids.
4. PFAS Destruction
Overview: PFAS (per- and polyfluoroalkyl substances) are a class of synthetic “forever chemicals” characterized by extremely strong C–F bonds. They are widely used (non-stick cookware, firefighting foams, stain repellents) but resist all conventional treatment. The only way to eliminate PFAS is to break the C–F bond, turning them into innocuous end-products (like CO₂, HF, salts). PFAS destruction technologies typically combine pre-concentration with destructive chemistry. Approaches include supercritical water oxidation (heating contaminated water above 374°C, oxidizing PFAS into CO₂ and mineral salts), electrochemical oxidation (PFAS are broken at anodes or specialized electrodes), photochemical or advanced oxidation (e.g. UV light with catalysts generates radicals that attack C–F), and plasma reactors (ionize PFAS in gas phase). Often, a filtration or ion-exchange step first concentrates PFAS from dilute water to a smaller volume, which is then treated by destruction.
Recent Advances: Around 2023–2026, PFAS destruction moved from lab demos to pilot-scale and beyond. Key progress includes: robust electrochemical cells able to continuously destroy PFAS in industrial effluent; UV-advanced oxidation systems deployed at sites; and records of continuous operations. For example, by 2024 a Michigan facility was operating continuously to destroy PFAS drawn from landfill leachate. Researchers at Daikin (a PFAS manufacturer) successfully ran an industrial trial treating 170,000 gallons of concentrated PFAS-laden wastewater with UV-based destruction. Importantly, regulatory action has spurred deployment: the EU in 2020 banned PFAS in drinking water, and the US EPA and states (as of 2023–2024) began adopting strict limits. This shifted the approach from “containment only” to “treat-and-eliminate.” Many new start-ups (e.g. EcoChem, BlueOval) and research consortia have emerged, often funded by governments.
Mechanisms and Sources: As described in [61], several PFAS-destruction mechanisms now exist. Supercritical water (a commercial process at some paper mills) dissolves PFAS and provides the needed energy to break C–F bonds. Electrochemical oxidation (often using high-potential or boron-doped diamond electrodes) strips electrons off PFAS, with tested success on short-chain PFAS. Photochemical methods (UV or UV/ozone with catalysts) target C–F via radicals. Each has trade-offs: high energy use and corrosion concerns. A 2024 review notes that combined processes (e.g. ultrafiltration + oxidation) achieve the highest destruction efficiencies, since concentrating PFAS makes the chemical processes viable. No single “silver bullet” exists yet; the trend is modular “treatment trains” tuned to specific waste streams.
Applications: The need is urgent across many domains. Municipal drinking water treatment plants (with PFAS in source water) have begun retrofitting destruction units, rather than only activated carbon filters. Industrial sites (chemical plants, tanneries, textile mills) are deploying on-site PFAS abatement. Consumer goods recycling (e.g. textile recycling) could require PFAS destruction to prevent recycling contamination. A particularly promising use is point-of-use treatment for firefighting foam runoff: e.g. state-of-the-art mobile units now exist. In specialty applications, PFAS destruction is critical for forward-looking military (cleaning up AFFF contamination) and airports. Due to high treatment cost, many small municipalities still choose source water avoidance, but this is changing as proof-of-concept plants operate.
Limitations/Challenges: PFAS destruction remains energy-intensive and costly. The field operations mentioned (Grand Rapids, Daikin) often still rely on expensive utilities (electricity, H₂O₂, etc.). Complete mineralization is hard: many methods produce fluoride ions that must be dealt with, and unreacted intermediates can persist. Validating “non-detect” destruction is itself difficult—measurement at <ppt levels is challenging. The economic model is unclear: if PFAS are ubiquitous, who pays? Legacy disposal sites (landfills, dumps) could be targeted, but requires massive investment. As the WEF report notes, scaling destruction hinges on regulatory frameworks that value destruction over mere containment. There is also a risk of “regulatory capture” if producers of PFAS (or of destruction equipment) unduly influence standards.
Ethical/Societal Implications: PFAS pose serious health risks (cancer, endocrine disruption), so methods that eliminate them are societally beneficial. On the other hand, widespread destruction could push more PFAS-containing products out of use (which is likely desirable). A key concern is environmental justice: PFAS contamination disproportionately affects some communities (e.g. near military bases). Equitable deployment of destruction tech—ensuring all communities can clean water—will be important. Transparency and trust are also ethical issues: companies and regulators must prove that “destroyed” truly means irrecoverable byproducts, not just dispersed. The use of AI and automation (as some suggest) in optimizing destruction must be careful not to let decisions (e.g. which PFAS to prioritize) embed biases.
Commercialization & Leading Organizations: The PFAS destruction sector is nascent but attracting attention. Startups like InterApplied, AquaHelix Environmental, and SenesTech are developing advanced oxidation systems. Big water treatment firms (e.g. Veolia, Jacobs) offer integrated solutions. Energy utilities are partnering with clean-tech firms for pilot plants. Companies like Daikin are investing directly in solutions (their trial is one example). TRL: First-generation destruction systems (supercritical oxidation) are TRL 8–9; newer adsorption-desorption-oxidation systems are TRL 6–7. WEF cites that U.S. demonstrations are “commercial-scale” as of 2023. Timelines suggest regional adoption by late 2020s, but global contamination may not be addressed until 2030+.
Future Directions: Research focuses on lowering energy costs (e.g. photothermal catalysts using sunlight), novel catalysts for C–F cleavage, and biotechnology (enzymatic defluorination is being explored). Advanced sensors to certify destruction (e.g. nanopore mass spec) are needed. Policy will drive much: stricter nationwide PFAS limits (as proposed in the US and EU) will force treatment. A promising development is electrochemical carbon-fluorine coupling: turning PFAS into useful compounds by controlled partial breaking—though still experimental. In summary, PFAS destruction technologies are transitioning from “emerging” to critical infrastructure, and ongoing R&D will determine their economic viability and environmental footprint.
5. Precision Fermentation
Overview: Precision fermentation uses genetically engineered microorganisms (typically yeast, bacteria or fungi) as “micro-factories” to produce specific molecules – proteins, fats, small chemicals – that normally come from plants, animals or petrochemicals. The process is: scientists identify the gene(s) encoding a target molecule (e.g. a milk protein, an egg-white protein, a pharmaceutical peptide), insert them into a microbe, and then culture the microbe in large fermenters. The microbe churns out the molecule as if it were its own, on sugar feedstocks. The product is then purified; it is chemically identical to the original (e.g. dairy protein made by yeast is identical to cow’s whey). This “go to the gene, not the cow” approach allows production in any location with energy and feedstock, decoupling supply from arable land or livestock.
Recent Advances: In 2021–2026, the field exploded. Key enablers were rapid DNA synthesis/assembly and AI-driven strain design, which compressed development time. For example, new AI tools predict optimal metabolic pathways in silico in months instead of years. The COVID-19 pandemic provided $79 billion of investment and mRNA/vaccine manufacturing infrastructure (sequencers, clean rooms), which the fermentation industry leveraged. As a result, multiple precision-fermented products reached market: in 2024 Nestlé launched a whey protein isolate made by fermentation, and American start-ups (e.g. Perfect Day, EVERY) scaled up chocolate, dairy, and egg white proteins. One notable case: the startup Vivici (backed by dairy giant Fonterra) produces beta-lactoglobulin (a whey protein) with 87% less water than dairy farms. R&D milestones include fermentation-derived eggs by start-ups like Change Foods, and even synthetic spider silk fibers for materials. Reviews note rapidly falling costs: a 2025 assessment found that fermentation can use <10% of the water of animal agriculture and less land.
Principles and Sources: The underlying principle is that DNA is code. Once the genome sequence for a molecule is known, the “program” can run in microbes. AI and automation (robotic bioreactors, high-throughput screening) form “biofoundries” that iterate many designs quickly. This is transforming R&D: projects that took a decade (like artemisinin fermentative production) now move in a few years. A 2025 paper on drug artemisinin (anti-malarial) highlighted how fermentation solved agricultural volatility. Precision fermentation thus unites synthetic biology and industrial bioprocessing.
Applications: Food and nutrition are prime markets: dairy and egg proteins (without animals), fats/oils (breastmilk fat, cocoa butter substitute), fermentation-derived coffee and chocolate components are in development. The cosmetics industry uses fermentation for rare peptides, enzymes, and fragrances (e.g. vanillin yeast). In pharma, fermentation is standard for biologics (insulin, antibodies), but now extends to novel therapies (pegylated proteins, complex natural products). A notable example outside health: Ginkgo Bioworks and Amyris engineer microbes to produce flavors, fragrances and even alternative materials (e.g. nylon precursors, bioplastics). In chemicals, fermentation can make “drop-in” replacements for petrochemicals (e.g. adipic acid, itaconic acid). Essentially, any industry reliant on plant or animal-derived molecules is a candidate. The WEF report notes cosmetics, supplements, building blocks and pharmaceuticals.
Limitations/Challenges: Major challenges include cost competitiveness and scale. Many fermentation processes currently cost 2–5x of animal-derived products, although costs are rapidly falling. Building out bioreactor capacity is capital-intensive – fermentation plants are expensive compared to conventional factories. There are also technical hurdles: proteins that require complex post-translational modifications (e.g. glycosylation) may need eukaryotic hosts (yeast/fungi) which are slower. Product safety/regulatory frameworks are still evolving globally. Some consumers have resistance to “lab-grown” food (though surveys show rising acceptance). There is also intellectual property complexity: patented microbial strains could lock out smaller producers. On the flip side, biocontainment (preventing GMO release) is a public concern. Finally, the transition poses socio-economic questions: shift from agriculture implies need for biosecurity (feedstock from crops), and potential job losses in farming regions.
Ethical/Societal Implications: Precision fermentation has major sustainability benefits: dramatically lower GHG emissions, water and land use compared to livestock or plantations (studies suggest >90% reductions in footprint). It can improve food security by localizing production (protein made in deserts or cold regions without farmland). Ethically, replacing animal products addresses animal welfare concerns and may reduce use of antibiotics in farming. However, there is risk of techno-colonialism: if large companies control gene sequences, small farmers could be marginalized. Ensuring equitable technology transfer to low-income countries is vital. Also, as WEF notes, the economic value shifts from agriculture to infrastructure (biofactories), which could harm rural economies. Managing this transition (retraining, community benefit sharing) is a societal priority.
Commercialization & Leading Organizations: Precision fermentation is already commercial at small scale. Leading firms include Perfect Day (animal-free dairy proteins), Motif FoodWorks and Geltor (specialty proteins), YeastFutures (moonshot projects), and Triton Algae (omega-3 oils). Big food companies (Nestlé, ADM, Barry Callebaut) have invested or launched products. Bio-pharma companies (BioNTech, GSK) use microbial platforms for vaccines and therapeutics. Key investors include Bill Gates’ Breakthrough Energy Ventures and Horizons Ventures. TRL is high for simple cases (e.g. single protein factories, TRL ~8–9). Complex molecules and larger-scale multi-protein products are mid-TRL (5–7). New “ferm labs” and biofoundries are expanding globally (Singapore, Germany, US). Time-to-market: some products (e.g. animal-free dairy) are already on shelves; mass adoption for mainstays (e.g. meat analogs or broad dairy replacement) is expected by 2028–2035.
Future Directions: The next frontier is multi-component fermentation (cocktails of microbes producing complex foods like cheese or seafood); also fermentation for cell-cultured meat scaffolds. AI will further optimize strains (AutoML for biology). Regulatory harmonization (analogous to GMP for foods) is likely. Genetic sequence libraries (open-source vs proprietary strains) will be a battleground. On the sustainability side, coupling fermentation with waste feedstocks (lignocellulosic sugars, agricultural residues) can close loops. Venture into fusion areas (e.g. precision fermentation + bioprinting of tissues) is emerging. In summary, precision fermentation is moving beyond novelty to an established method in the bioeconomy, with vast growth potential.
6. Exosome Drug Delivery
Overview: Exosomes are natural extracellular vesicles (30–150 nm) that cells release to communicate. They carry proteins, lipids and nucleic acids and can cross biological barriers. Exosome drug delivery harnesses these as stealthy carriers: drugs (small molecules, RNA, proteins) are loaded into exosomes engineered to target specific tissues. Because exosomes are “self” particles (derived from patient’s cells or bioreactors), the immune system typically tolerates them, and they can traverse the bloodstream, pass the blood-brain barrier, and target cancer or other diseased cells. Unlike synthetic nanoparticles, exosomes have natural homing signals (surface proteins) and excellent biocompatibility. The key principle is exploiting the body’s own couriers for precision therapy.
Recent Advances: Until recently, exosomes were mostly studied biologically. In 2020s, enabling technologies converged: high-yield bioreactors and purification (3D culture systems, tangential flow filtration) raised exosome yields 10–50×. Genetic engineering can display targeting peptides on exosome surfaces. Clinically, regulatory clarity arrived: in 2022 the FDA/EMA categorized exosome therapies as biologics, providing a regulatory path. As a result, by 2023 over 200 clinical trials were registered on exosome therapies (cancer, neurodegeneration, inflammation). Notable milestones: In 2023 a Phase-1 trial at MD Anderson showed engineered exosomes against pancreatic cancer mutations stabilized disease in patients who had no other options. In early 2025, another study demonstrated exosome-encapsulated gene editors crossing the blood–brain barrier to neurons without immune reaction – a proof of concept for treating Alzheimer’s or Parkinson’s. Venture investment is surging: e.g. Eli Lilly invested $1.5B in Evox Therapeutics (exosome delivery startup) in 2023.
Principles and Sources: The literature emphasizes exosomes’ natural delivery advantages. They protect cargo from degradation and evade phagocytosis. Loading techniques (donor cell transfection, electroporation) can package siRNA, mRNA, proteins. A 2024 review notes that exosomes have delivered diverse payloads (chemotherapeutics, nucleic acids) effectively to tumors in mice. The WEF report’s Figure 6 notes brain delivery as a standout potential. Key research also focuses on surface modification (e.g. Lamp2b fusion peptides) for targeting. The field still lacks standard potency assays, which hampers consistent clinical translation.
Applications: The most urgent applications are in oncology and neurology. Exosomes can penetrate tumors and the brain; for example, glioblastoma and Alzheimer’s have few drug options due to the blood–brain barrier. Early trials are targeting pancreatic and brain cancers with exosome-delivered immunotherapies. Others are using exosomes for regenerative medicine (delivering growth factors to wounds) and rare diseases (mRNA or CRISPR to hard-to-reach tissues). Exosomes also show promise as vaccines or immune modulators (e.g. cancer vaccines presenting tumor antigens via exosomes). Another area is diagnostics: exosomal content (from blood) can serve as biomarkers, although that’s ancillary to “delivery”. Importantly, exosome delivery may supplant some viral vectors and lipid nanoparticles (LNPs) for certain gene therapies, offering lower immunogenicity.
Limitations/Challenges: Critical obstacles remain. Manufacturing at scale is hard: producing homogeneous exosomes with defined cargo/size is more complex than synthesizing LNPs. Biological variability (exosomes from different cell sources behave differently) complicates standardization. Potency assays are not established (how to measure a “dose” of exosomes equivalently?). There are safety concerns: exosomes can carry unwanted signals (oncogenic factors) if not thoroughly purified. Immunogenicity is low but not zero; one must ensure no viral or prion contaminants. Clinically, targeting specificity is still imprecise; off-target effects could occur if exosomes bind healthy cells. Also, storage stability is an issue (they may require ultra-cold storage similar to some biologics). Finally, the regulatory pathway, though emerging, still lacks precedence, requiring careful navigation.
Ethical/Societal Implications: Exosome therapies hold the promise of treating diseases that currently have no cure (advanced cancer, neurodegeneration) – a profound societal benefit. Personalized exosome medicine (using a patient’s own cells) raises issues similar to cell therapies (e.g. cost and access). If engineered exosomes carry DNA/RNA payloads, there will be scrutiny on long-term effects. Data privacy is indirect but relevant: as with any advanced therapy, if only wealthy patients or nations can afford it, disparities could widen. Ethically, using “self” particles may ease acceptance versus synthetic nanotech. A subtle risk: if off-target impacts on the brain/immune system occur, they may not be detected until late, so rigorous oversight is needed. Overall, the high medical potential suggests strong ethical imperative to develop these safely and equitably.
Commercialization & Leading Organizations: Several biotech firms specialize in exosome delivery: Evox Therapeutics (UK) is a leader in systemically delivered exosome therapies; Ascletis (China) has liver cancer exosomes in trials; Codiak BioSciences (US) focuses on exosome engineering. Big pharma is engaged: in addition to Lilly/Evox, Pfizer has a collaboration with Codiak, and BridgeBio is working on exosome-delivered gene therapy. Universities (Stanford, MIT, King’s College London) run translational labs. TRL is mixed: basic technology (exosome isolation/purification) is TRL 6–7; engineered therapeutic exosomes (Phase I/II trials) are TRL 5–6. Commercial drugs (FDA-approved) may still be 3–5 years away. Investment is ramping: a recent market report projects the global exosome therapeutics market hitting $1B by 2030. Given the steep R&D and manufacturing needs, widespread use is probably a decade away for mainstream conditions.
Future Directions: Research aims to improve cargo loading (bio-orthogonal chemistry or endogenous packaging), targeting specificity (designer surface ligands), and yields (bioreactor cell lines engineered to hyper-produce exosomes). There is also interest in synthetic exosome mimetics – artificial vesicles combining natural and synthetic lipids for more control. The overlap with mRNA and gene therapy is notable; for example, exosomes might deliver CAR mRNA to T-cells in vivo. Standardization efforts are underway (International Society for Extracellular Vesicles guidelines). In parallel, AI-driven modeling of vesicle trafficking could accelerate design. If successful, exosome delivery could become a platform technology underpinning many future biologics, transforming “hard-to-drug” conditions into tractable ones.
7. Personalized mRNA Cancer Vaccines
Overview: Personalized mRNA cancer vaccines are immunotherapies tailored to an individual’s tumor genetics. Unlike traditional drugs that attack tumors directly, these vaccines teach the patient’s immune system to recognize cancer cells. The process is: biopsy the tumor, sequence its DNA/RNA, identify neoantigens (mutated proteins) unique to the cancer, and then synthesize an mRNA encoding those neoantigens. The mRNA is formulated in lipid nanoparticles and injected into the patient, where cells produce the tumor proteins and present them to the immune system, priming T-cells to attack any cells bearing those antigens. The result is a truly personalized therapy based on the patient’s own tumor biology. Key enablers are the rapid sequencing and synthesis infrastructure (pioneered for COVID-19 vaccines) and advances in neoantigen prediction algorithms.
Recent Advances: The COVID-19 pandemic accelerated this field enormously. mRNA vaccine platforms went from lab to global scale in months, shrinking timelines for personalized vaccine development. By 2026, several trials have reported breakthrough results. The WEF report highlights that a 6-year trial at Memorial Sloan-Kettering for pancreatic cancer (survival ~13% normally) showed 90% six-year survival among patients whose immune system responded to a custom mRNA vaccine. Another study on high-risk melanoma combined a personalized mRNA vaccine with pembrolizumab (Keytruda): recurrence risk was cut by 49% compared to immunotherapy alone. These outcomes have galvanized the field: in March 2026, the US National Cancer Institute announced $200M for next-generation personalized vaccine trials. Over a dozen biotech companies (e.g. BioNTech, Moderna, Gritstone, Genenta) are developing pipelines, moving beyond proof-of-concept.
Principles and Sources: The science builds on two pillars: oncology genomics and mRNA technology. Decades of cancer genome mapping have shown that most tumors harbor unique mutation fingerprints. mRNA vaccines, proven safe in millions of people for COVID, provide the rapid, flexible delivery method. Key literature notes that sequencing and manufacturing costs plummeted after 2020. WEF cites $79.4B public investment in mRNA globally during the pandemic, which also validated portable mRNA factories. Thus, personalized cancer vaccines moved from theory to reality: as one source quips, each vaccine’s “bioreactor is the patient’s tumor DNA”.
Applications: This approach is being tested in many cancers: melanoma, non-small cell lung cancer, glioblastoma, pancreatic, colorectal, etc. It is especially promising for hard-to-treat or immunologically “cold” tumors. Early use cases focus on two settings:
- Adjuvant therapy: After surgery removes a tumor, a vaccine is given to eradicate residual micrometastases. (E.g. the melanoma trial.)
- Late-stage salvage therapy: For metastatic cancers with few options, vaccines aim to control disease. (E.g. the pancreatic trial.)
Because each vaccine is unique, manufacturing is modular. Hospitals could conceivably host “plug-and-play” mRNA production units. One illustration imagines a biopsy on Monday, sequencing Tuesday, vaccine ready by Thursday. Beyond oncology, this personalized approach may extend to infectious diseases (custom influenza vaccines) or autoimmunity in future, but cancer is the current focus.
Limitations/Challenges: Personalized vaccines face major hurdles. First, manufacturing speed and scale: producing an individualized drug per patient is logistically complex and expensive compared to “one-size-fits-all” medications. Quality control and GMP compliance for each batch are burdensome. TRL for end-to-end systems is mid-level. Second, regulatory: existing frameworks handle mass-produced biologics, not thousands of unique ones. New approval models (n-of-1 trials, adaptive protocols) must emerge. Third, biological variability: not all patients generate a strong immune response; the biology of antigen processing is still not fully controllable. The targets themselves may evolve (tumor heterogeneity). Fourth, equity: sequencing tumors for every patient may be harder in low-resource settings. Finally, tumor-immune escape is a risk (tumors mutating away from targeted antigens).
Ethical/Societal Implications: Personalized vaccines blur the line between patient and drug, making each patient’s tumor the “raw material” for therapy. This raises intellectual property questions (who owns the neoantigen sequences?) and ethical issues of consent for genomic data use. If successful, the approach could significantly improve survival for cancers that currently have grim prognoses (societal good). However, unequal access could widen health disparities: wealthier health systems may adopt this high-cost therapy first. Ensuring that pipelines exist globally is a challenge. Psychologically, this empowers a “precision medicine” narrative – a patient’s unique mutation is harnessed for cure – which may raise patient expectations (for better or worse).
Commercialization & Leading Organizations: Clinical trials (often industry-sponsored) are underway at major cancer centers (MSKCC, MD Anderson, NCI). Key companies: BioNTech partnered with Genentech for personalized vaccines; Moderna has oncology R&D; Gritstone and Genocea focus on neoantigen vaccines; UCSF’s Vaxix (allogeneic) showcases rivals in the space. Vaccine production companies like IDT or Ion Torrent are scaling sequencing-to-mRNA workflows. TRL is around 5–6 (active clinical development). Time-to-market: Realistic projections suggest initial approvals (for specific indications) by 2030, with broader adoption by mid-2030s, given necessary trials and manufacturing build-out.
Future Directions: Key R&D directions include AI for better neoantigen prediction (to select the most immunogenic targets), oncolytic viruses combining mRNA release, and combination therapies (vaccines with checkpoint inhibitors, as trialed). Technical advances may automate the pipeline end-to-end. For instance, an implanted implant or “vaccination kiosk” that sequences tumor fragments and directly prints mRNA is conceptually possible. Regulatory innovations (model-based approvals, shared epitopes) will be needed. Ultimately, we may see “cancer vaccine libraries” covering common mutations, or off-the-shelf neoantigen mixes for certain cancer subtypes. If costs drop sufficiently, this approach could become a standard part of oncology, shifting the cancer paradigm to prevention/early intervention in recurrence.
8. Quantum Simulation for Drug Discovery
Overview: Quantum simulation uses quantum computers to model molecular systems at the level of quantum mechanics, rather than using approximations. Conventional computers must simplify molecular electronic structure, but a quantum computer encodes and processes the Schrödinger equation directly. In practice, quantum bits represent atomic orbitals, allowing simulation of how a drug molecule really folds, binds or reacts. The promise is dramatically improved prediction accuracy for complex molecules, which can “change what diseases are worth pursuing”. Key principles include qubit coherence and entanglement for representing correlated electrons, and hybrid algorithms (classical optimization + quantum subroutines) that make such simulations feasible on near-term devices.
Recent Advances: In the past 5 years, hardware and algorithms have reached important milestones. Error mitigation and correction have advanced sufficiently that small but chemically meaningful simulations are now possible. Crucially, “the quantum drug discovery market roughly doubled in value over the past five years” as industry invested. High-profile demonstrations include: in 2025, IBM and Moderna ran the largest protein-folding and mRNA-simulation task on a quantum computer yet, folding a small protein beyond classical reach. In France, Pasqal and Qubit Pharmaceuticals began using neutral-atom quantum machines for drug-like molecules. Algorithms like VQE (variational quantum eigensolver) and QAOA have been tailored for drug targets. These demonstrate that simulating molecules of ~50–100 atoms might soon be routine on fault-tolerant devices expected in the 2030s.
Principles and Sources: The WEF text notes that quantum simulation provides “a molecular portrait with a level of fidelity that classical computing cannot match”. This fidelity means more accurate binding energies and reaction pathways. It cites IBM/Moderna’s 2025 result as “proof” of capability. Academic work (e.g. Gupt et al. 2024, Reiher 2023) reports quantum algorithms solving model drug problems (like the enzymatic active sites or small protein folds) that challenge supercomputers. As hardware scales (from ~100 to 1000 qubits), simulating candidate drug molecules (e.g. opiates, antivirals) becomes feasible.
Applications: Pharmaceutical R&D is the primary application. Quantum simulation can help in lead optimization (precisely predicting binding to proteins), reaction mechanism exploration (synthesizing complex molecules), and novel scaffold discovery (features unreachable by classical design). It is especially promising for “hard” targets: protein–protein interfaces, flexible metalloenzymes, RNA structures, etc. If simulation reduces failure rates, it could lower the cost of developing drugs for rare or neglected diseases by identifying viable candidates faster. Financially, this is very attractive: the industry spends $30B/year on R&D, often with <1% success. Better in silico prediction shifts value to earlier stages. Other areas include materials science (new drug-delivery materials) and even quantum-enabled discovery of new antibiotics by exploring large chemical spaces.
Limitations/Challenges: Quantum hardware remains very limited. Current quantum computers are noisy and have few logical qubits; simulating anything but toy molecules is still experimental. TRL is low (~3–4). It may take 5–10 years to get error-corrected machines for moderately sized drug candidates. Even then, algorithmic challenges persist (convergence of hybrid optimizers, need for benchmarking standards). Integration into pharma pipelines requires interoperability (classical/quantum workflows) and validation by regulators. Cost of quantum computers is also a barrier, though cloud-based access (IBM Quantum, IonQ Cloud, AWS Braket) is increasing availability. Lastly, talent shortage in quantum chemistry and programming is a bottleneck.
Ethical/Societal Implications: If quantum simulation can enable cures for previously “undruggable” diseases (e.g. Alzheimer’s, amyloidoses), the impact is immense. However, it may also widen the innovation gap: only well-funded pharma or nations might harness this technology initially, potentially exacerbating global health inequities. On the flip side, it could drastically accelerate response to pandemics (rapid vaccine adjuvant or antiviral design). Another consideration: simulation of dangerous pathogens’ features could dual-use (biothreat analysis). Strong access controls and ethical governance will be needed. The power of quantum to transform R&D also raises issues of “who owns discoveries made computationally” vs. serendipitous screening.
Commercialization & Leading Organizations: Major tech companies (IBM, Google, Microsoft, Amazon) are heavily involved in quantum computing platforms. In pharmaceuticals, Merck, Novartis, and GlaxoSmithKline have partnerships with quantum startups (e.g. D-Wave, Cambridge Quantum) to explore quantum drug design. Startups like Qubit Pharmaceuticals, MolBio, and Rahko (quantum machine learning) are pursuing niche applications. The U.S. and EU have launched quantum initiatives, with multi-billion-dollar investments. TRL for specific drug design use-cases is around 4–5; some say partial adoption could occur in the late 2020s in biotech labs. A practical timeline might see hybrid quantum-classical simulations complementing classical methods by 2030, reaching transformative power by the 2030s.
Future Directions: Research goals include developing error-corrected qubits (superconducting, trapped-ion), quantum machine learning for molecule generation, and tighter pharma-quantum collaboration. Cross-disciplinary education (quantum chemists, drug developers) is growing. Adaptive regulatory science will be needed: can a quantum-predicted drug be pre-approved for trial? International standards may emerge for simulation validation. Long term, quantum methods could democratize discovery: distributed quantum cloud services might let any lab screen libraries of compounds. Even before full fault-tolerance, specialized “analog quantum simulators” (e.g. Rydberg atom arrays) might tackle specific bio-problems (as Pasqal is doing). The field is fast-moving – a decade from basic research to routine tools is plausible.
9. World Models in AI
Overview: World models are AI systems that learn a rich, internal representation of the physical world from multi-sensory data, enabling them to predict and plan in three dimensions. Inspired by human learning, these models ingest video, depth, motion and other sensor inputs simultaneously and compress them into a unified latent space representing the state of the world. For example, the sight of a falling apple, the sound of its thud, and physics equations describing gravity all map to the same concept in the model’s memory. The core insight (Yann LeCun’s JEPA) is to train networks not to reproduce raw pixels but to predict future states, thereby capturing dynamics like object movement. The result is an AI “mental model” that understands physics and can simulate outcomes of actions.
Recent Advances: Until recently, training such models required unrealistically large data and compute. Two breakthroughs changed that: (1) Deep learning architectures (transformers, joint-embedding) scaled to combine modalities. (2) Surplus of training data from autonomous vehicles, robotics, IoT (~20 million hours of sensory data) became available. In 2025 Nvidia launched Cosmos – a “video foundation model” trained on robot and driving data, which enables robots to generalize learned behaviors to new environments. In 2026, Stanford researchers showed that integrating a world model into climate simulations improved storm prediction accuracy. These examples demonstrate that AI with an internal world model can plan or infer physics in ways older AI (which only saw data in narrow contexts) could not. OpenAI and DeepMind have released research on similar multimodal predictive models.
Principles and Sources: The WEF analysis emphasizes that world models “capture patterns of events, not the medium”. LeCun’s 2022 JEPA work is foundational: instead of pixel-level reconstruction, the model learns abstract state. This enables better generalization: e.g., an agent can predict the trajectory of a bouncing ball it has never seen, by extrapolating physics. World models thus provide a kind of intuition (like a physics engine) for AI. The Nvidia example shows the transition from lab to deployment: the report notes Cosmos-trained robots can navigate unfamiliar layouts because they reason from internal models, not memorized routes. Another study trained a world model for complex game environments (e.g. Minecraft), enabling zero-shot adaptation.
Applications: World models could revolutionize robotics, autonomous systems and scientific discovery. In robotics/manufacturing, robots using a world model could adapt to novel tasks or environments without retraining. For industrial automation, such AI could foresee machine failures or optimize workflows by simulating outcomes. In transportation (self-driving cars), world models might enhance safety by predicting rare events beyond training data. In healthcare, multi-modal patient data (imaging + vitals) might feed into a patient “health model” that predicts disease progression. The climate example suggests use in Earth sciences – improving forecasts of weather or materials behavior. Even in entertainment (VR/AR), AI world models could generate realistic dynamic scenes. Notably, WEF points out world models could move AI from just “observing” to “actively informing decisions in real-world settings”.
Limitations/Challenges: Constructing accurate world models is resource-intensive. They require vast aligned datasets (video+sensor+annotations) which many fields lack. Also, learned models may latch onto spurious correlations; e.g. if training data is biased, the model’s “physics” could be wrong (the report warns models might build flawed assumptions). Validation is hard: how to verify an AI’s internal model of the world is correct? Safety is a concern – a world-model-driven system might take actions based on erroneous predictions, with real-world consequences. Computational cost is high: such models run on large GPUs and are not yet efficient for edge devices. Ethically, these AIs have a powerful “imagination” – misuse could involve generating deceptive simulations or controlling agents in unexpected ways. Transparency (explaining how the model works) is also a challenge, as the internal representations are latent and complex.
Ethical/Societal Implications: If world models succeed, they could boost automation and productivity across industries. This has economic benefits but also social impacts (job displacement in routine planning roles). On the positive side, safer AI in cars and factories is possible. Ethically, embedding such models in critical infrastructure raises questions of oversight: governments may need to audit world model systems for bias. Additionally, because world models learn from data about people’s environments, there could be privacy concerns (learning from surveillance footage, for instance). The technology could also accelerate research (for good), but its power must be handled responsibly – e.g. autonomous weapons with flawed world models would be dangerous. Overall, the broad cognitive leap means a need for strong governance and “interpretability-by-design”.
Commercialization & Leading Organizations: Tech giants like NVIDIA, Google DeepMind, OpenAI, and Tencent AI Lab are at the forefront. NVIDIA’s Cosmos is one of the first commercial initiatives, and robotics companies (ABB, Boston Dynamics) are exploring integration. Startups (e.g. Embodied Intelligence, CogitAI) work on applying world models to automation. In academia, MIT, Stanford, and CMU have dedicated labs. TRL is still early: general-purpose world models are in research/prototype stage (TRL ~4–5). However, smaller domain-specific models (e.g. for factory robotics) might be at TRL 6–7 soon. Widespread adoption in safety-critical systems likely 2030+. The development timeline is moving rapidly – NVIDIA’s work shows large corporations are racing to capture this paradigm.
Future Directions: Research will refine model architectures (e.g. better compression, continuous learning). A key area is causal learning: enabling models to learn cause-effect in the world (beyond correlation) to improve robustness. Benchmarking world models in real environments (reinforcement learning) is a growing focus. Integration with digital twins and simulation tools is expected: the WEF suggests funding should shift from isolated labs to AI-simulation-automated platforms that close the loop between theory and experiment. Ethicists propose developing “override” mechanisms so human operators retain ultimate control (the report stresses oversight frameworks). On the application side, we may see world-model based copilots (in factories or hospitals) by 2030. In sum, world models represent a paradigm shift in AI – from pattern recognition to physics-based reasoning – and will unfold through continued R&D and cross-sector alliances.
10. Lattice-Based Cryptography
Overview: Lattice-based cryptography is a suite of encryption methods designed to be secure against quantum computers. In classical public-key crypto (RSA, ECC), security relies on problems (factoring, discrete log) which quantum algorithms (Shor’s) can solve efficiently. Lattice cryptography instead hides messages within hard lattice problems. Roughly speaking, data is encrypted into points of a high-dimensional lattice with added random “noise” (like a fog) that makes finding the exact point extremely difficult. Even a quantum computer cannot easily invert this: the “small errors” in the ciphertext make every plausible solution almost equally valid, so distinguishing the true message is infeasible. Some lattice schemes enable additional features like fully homomorphic encryption (FHE), allowing computation on ciphertexts without decryption.
Recent Advances: The last few years have seen lattice crypto move from theory to deployment. Major milestones include: in 2023–24, NIST selected lattice-based algorithms as finalists for post-quantum encryption standards. By 2024, NIST adopted lattice-based algorithms (Kyber, Dilithium) as the first PQC standard. Cryptosystems using these primitives are now being built (e.g. Kyber for key exchange, CRYSTALS-Dilithium for signatures). Fully homomorphic encryption (a long-sought goal) made practical strides: in 2024, researchers at Asan Medical Center demonstrated training an AI on multi-institutional patient data using FHE, without sharing raw data. Industry is acting: Google announced plans to migrate all data channels to quantum-resistant cryptography by 2029. Financial and government networks (SWIFT, global 200 banks) are actively preparing transitions to post-quantum standards. Standards bodies (ISO, ETSI) have aligned on lattice schemes. This rapid progress is a direct response to the “harvest now–decrypt later” threat.
Principles and Sources: Lattice cryptosystems (e.g. Learning With Errors, Ring-LWE) are well-studied in theory for decades. The WEF report explains their core idea with the “noise as fog” analogy. The added randomness makes the decoding a combinatorial search in high dimensions – even quantum algorithms offer only limited speedups (essentially square-root) which is made negligible by high dimensions. A key source on quantum resilience is the NIST PQC project (2022-24), which selected only lattice schemes (Kyber for encryption, others for signatures) after thorough evaluation. Experts emphasize that lattice cryptography is believed quantum-hard (NIST and NSA’s roadmap) and also offers classical advantages (e.g. fast arithmetic, no number-theoretic traps). The WEF text also highlights fully homomorphic encryption (FHE) – an advanced lattice-based construction that “allows computations on encrypted data without decryption”. FHE experiments (like the 2024 Asan trial) show new possibilities for data privacy, trust and collaboration.
Applications: The primary driver is quantum-safe encryption. Any sensitive data that must remain confidential for decades (national secrets, medical records, financial data) needs lattice encryption now to prevent future decryption. Government agencies (NSA, EU), defense, and critical infrastructure are mandatory adopters. Major finance networks (SWIFT) plan to upgrade to lattice cryptography by 2025–2030. Beyond that, lattice crypto’s features open new applications. For example, real-time data analytics on encrypted databases (hospitals, IoT networks) become feasible via FHE, enabling privacy-preserving AI. Cryptographic protocols like digital signatures, secure key exchange, and blockchain integrity can all be made quantum-resistant with lattice primitives. Lattice cryptography also supports “identity-based encryption” schemes and other advanced cryptographic constructs (e.g. attribute-based encryption) that could enhance multi-stakeholder systems.
Limitations/Challenges: While powerful, lattice schemes come with trade-offs. Key sizes and ciphertexts are larger than classical RSA/ECC, leading to bandwidth and storage overheads (though still reasonable). Performance overhead (computationally heavier math) can be 10–100× classical crypto, requiring hardware acceleration for high-speed use. Implementing these schemes correctly is nontrivial; side-channel resistance must be ensured. There is also cryptanalysis risk: although lattices are currently secure, new attacks could theoretically appear (though most experts believe lattice problems to be robust). Transition complexity is a challenge: replacing cryptographic libraries across billions of devices is a massive engineering effort. For FHE, efficiency is still low, making it suitable only for batch or niche tasks now (but improving rapidly).
Ethical/Societal Implications: Lattice cryptography essentially secures society’s data against a future “quantum threat.” This is an ethical imperative for privacy and security. By enabling computation on encrypted data (FHE), it can facilitate valuable data sharing (e.g. medical research across hospitals) without revealing patient info. This could reduce data monopolies and empower collaborative science. However, by strengthening encryption, it also potentially hinders law enforcement (making wiretapping or metadata analysis impossible unless backdoors are created). Debate over “going dark” will intensify; many jurisdictions fear that unbreakable encryption prevents crime prevention, while privacy advocates demand no weakened security. Ensuring open, transparent standards (so all get secure tools) is important to avoid geopolitical divides. Notably, developing nations need access to this crypto too – open standards help ensure non-exportability. Also, any centralization of “quantum-proof” keys or CAs (certificate authorities) could become a new security bottleneck.
Commercialization & Leading Organizations: Because of its strategic importance, lattice crypto is moving into products. Microsoft has already begun shipping lattice-based signature algorithms in some libraries, and Google Chrome/Android are adding post-quantum support (Chrome 110 beta in 2023). Crypto hardware firms (Thales, Entrust, IBM Security) are releasing PQC firmware updates. The open-source community (OpenSSL, BoringSSL) has integrated lattice algorithms (e.g. CRYSTALS). NIST’s choice has galvanized the industry: many governments and enterprises now have transition roadmaps. TRL is high for the algorithms themselves (mathematically solid – TRL 8–9), but full-system implementation (end-to-end encrypted communication) is mid-stage (TRL ~5–6 in network products). However, national mandates (EU decree, NSA directive) mean that by 2025–2027 many new devices will ship quantum-safe. Full replacement of legacy crypto across the Internet may extend to 2030–2035.
Future Directions: Ongoing work includes optimizing implementations (e.g. hardware accelerators for lattice operations) and exploring exotic lattices (for example, to enable richer functionality). The concept of “crypto agility” (software updateability for crypto algorithms) will become standard. In the longer term, combining lattice cryptography with quantum key distribution might provide layered security. Research into novel lattice-based primitives (zero-knowledge proofs, multiparty computation) is vibrant. Standards bodies (ISO/IEC) continue to publish PQC guidelines. Ultimately, the post-quantum era will normalize these methods: encryption on devices by default will be lattice-based. The emphasis may shift to usability and interoperability (e.g. ensuring legacy systems and developing world technologies adapt). If all goes well, by 2030 lattice-based methods will be as ubiquitous as AES/RSA is today, quietly protecting digital life against tomorrow’s computers.
Editor: Ayesha Noor